Loncar Cancer Immunotherapy Etf Market Value
CNCR Etf | USD 12.71 0.28 2.25% |
Symbol | Loncar |
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Loncar Cancer 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Loncar Cancer's etf what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Loncar Cancer.
02/28/2023 |
| 02/17/2025 |
If you would invest 0.00 in Loncar Cancer on February 28, 2023 and sell it all today you would earn a total of 0.00 from holding Loncar Cancer Immunotherapy or generate 0.0% return on investment in Loncar Cancer over 720 days. Loncar Cancer is related to or competes with Virtus LifeSci, Virtus LifeSci, and ALPS Medical. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by th... More
Loncar Cancer Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Loncar Cancer's etf current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Loncar Cancer Immunotherapy upside and downside potential and time the market with a certain degree of confidence.
Information Ratio | (0.13) | |||
Maximum Drawdown | 8.63 | |||
Value At Risk | (4.83) | |||
Potential Upside | 2.93 |
Loncar Cancer Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Loncar Cancer's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Loncar Cancer's standard deviation. In reality, there are many statistical measures that can use Loncar Cancer historical prices to predict the future Loncar Cancer's volatility.Risk Adjusted Performance | (0.08) | |||
Jensen Alpha | (0.31) | |||
Total Risk Alpha | (0.31) | |||
Treynor Ratio | (0.27) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Loncar Cancer's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Loncar Cancer Immuno Backtested Returns
Loncar Cancer Immuno has Sharpe Ratio of -0.0305, which conveys that the entity had a -0.0305 % return per unit of risk over the last 3 months. Loncar Cancer exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Loncar Cancer's Standard Deviation of 2.33, risk adjusted performance of (0.08), and Mean Deviation of 1.85 to check out the risk estimate we provide. The etf secures a Beta (Market Risk) of 1.14, which conveys a somewhat significant risk relative to the market. Loncar Cancer returns are very sensitive to returns on the market. As the market goes up or down, Loncar Cancer is expected to follow.
Auto-correlation | -0.41 |
Modest reverse predictability
Loncar Cancer Immunotherapy has modest reverse predictability. Overlapping area represents the amount of predictability between Loncar Cancer time series from 28th of February 2023 to 23rd of February 2024 and 23rd of February 2024 to 17th of February 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Loncar Cancer Immuno price movement. The serial correlation of -0.41 indicates that just about 41.0% of current Loncar Cancer price fluctuation can be explain by its past prices.
Correlation Coefficient | -0.41 | |
Spearman Rank Test | -0.02 | |
Residual Average | 0.0 | |
Price Variance | 1.79 |
Loncar Cancer Immuno lagged returns against current returns
Autocorrelation, which is Loncar Cancer etf's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Loncar Cancer's etf expected returns. We can calculate the autocorrelation of Loncar Cancer returns to help us make a trade decision. For example, suppose you find that Loncar Cancer has exhibited high autocorrelation historically, and you observe that the etf is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
Timeline |
Loncar Cancer regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Loncar Cancer etf is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Loncar Cancer etf is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Loncar Cancer etf over time.
Current vs Lagged Prices |
Timeline |
Loncar Cancer Lagged Returns
When evaluating Loncar Cancer's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Loncar Cancer etf have on its future price. Loncar Cancer autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Loncar Cancer autocorrelation shows the relationship between Loncar Cancer etf current value and its past values and can show if there is a momentum factor associated with investing in Loncar Cancer Immunotherapy.
Regressed Prices |
Timeline |
When determining whether Loncar Cancer Immuno is a strong investment it is important to analyze Loncar Cancer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Loncar Cancer's future performance. For an informed investment choice regarding Loncar Etf, refer to the following important reports:
Check out Loncar Cancer Correlation, Loncar Cancer Volatility and Loncar Cancer Alpha and Beta module to complement your research on Loncar Cancer. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Loncar Cancer technical etf analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, etf market cycles, or different charting patterns.